AstraZeneca Pharma India Limited
HEALTH/PHARMA AstraZeneca launches its patented life-saving heart drug BRILINTA ® (Ticagrelor) in India BRILINTA works by preventing the formation of new blood clots and maintaining blood flow in the body to help reduce patient’s risk of another cardiovascular event (called atherothrombotic events) such as a heart attack or cardiovascular death . AstraZeneca Pharma India Limited (AZPIL) announced the launch of a new patented antiplatelet drug BRILINTA (Ticagrelor) in India. BRILINTA is an oral antiplatelet treatment for Acute Coronary Syndromes (ACS) in adult patients. BRILINTA is competitively priced to enable ACS patients benefit from having access to this medicine. BRILINTA ® works by preventing the formation of new blood clots and maintaining blood flow in the body to help reduce patient’s risk of another cardiovascular event (called atherothrombotic events) such as a heart attack or cardiovascular death. The Drug Controller Gen...